4.8 Article

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

期刊

NATURE COMMUNICATIONS
卷 6, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/ncomms7336

关键词

-

资金

  1. Cancer Research UK [CR-UK A/16459]
  2. U-Care
  3. Genomic Medicine Theme of the Oxford NIHR Comprehensive Biomedical Research Centre
  4. Spanish Ministerio de Economia y Competitividad
  5. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  6. Krebsliga beider Basel [11-2011]
  7. Krebsliga Zentralschweiz
  8. Wellcome Trust Centre for Human Genetics from the Wellcome Trust [090532/Z/09/Z]
  9. European Union Framework 7 PREDICT, RESPONSIFY
  10. European Research Council (THESEUS) grants
  11. Breast Cancer Research Foundation
  12. Prostate Cancer Research Foundation
  13. Rosetrees Trust
  14. EU ERC EVOCAN award
  15. RMH/ICR NIHR Biomedical Research Centre for Cancer
  16. Academy of Medical Sciences (AMS) [AMS-SGCL2-Tran] Funding Source: researchfish
  17. Cancer Research UK [19310, 17786] Funding Source: researchfish
  18. Rosetrees Trust [M179] Funding Source: researchfish
  19. The Francis Crick Institute [10174, 10170, 10359, 10172, 10002, 10001, 10303, 10169] Funding Source: researchfish

向作者/读者索取更多资源

Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes of 31 pRCCs, and in four tumours, multi-region sequencing is undertaken. We identify BAP1, SETD2, ARID2 and Nrf2 pathway genes (KEAP1, NHE2L2 and CUL3) as probable drivers, together with at least eight other possible drivers. However, only similar to 10% of tumours harbour detectable pathogenic changes in any one driver gene, and where present, the mutations are often predicted to be present within cancer sub-clones. We specifically detect parallel evolution of multiple SETD2 mutations within different sub-regions of the same tumour. By contrast, large copy number gains of chromosomes 7, 12, 16 and 17 are usually early, monoclonal changes in pRCC evolution. The predominance of large copy number variants as the major drivers for pRCC highlights an unusual mode of tumorigenesis that may challenge precision medicine approaches.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据